SG166019A1 - Quinoline derivatives and use thereof as mycobacterial inhibitors - Google Patents

Quinoline derivatives and use thereof as mycobacterial inhibitors

Info

Publication number
SG166019A1
SG166019A1 SG200902708-7A SG2009027087A SG166019A1 SG 166019 A1 SG166019 A1 SG 166019A1 SG 2009027087 A SG2009027087 A SG 2009027087A SG 166019 A1 SG166019 A1 SG 166019A1
Authority
SG
Singapore
Prior art keywords
quinoline derivatives
general formula
forms
mycobacterial
mycobacterial inhibitors
Prior art date
Application number
SG200902708-7A
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
Elisabeth Therese Jeanne Pasquier
David Francis Alain Lancois
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG166019A1 publication Critical patent/SG166019A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
SG200902708-7A 2004-01-23 2005-01-21 Quinoline derivatives and use thereof as mycobacterial inhibitors SG166019A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53890704P 2004-01-23 2004-01-23

Publications (1)

Publication Number Publication Date
SG166019A1 true SG166019A1 (en) 2010-11-29

Family

ID=34807238

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902708-7A SG166019A1 (en) 2004-01-23 2005-01-21 Quinoline derivatives and use thereof as mycobacterial inhibitors

Country Status (29)

Country Link
US (2) US7902225B2 (fr)
EP (1) EP1711181B1 (fr)
JP (1) JP4879755B2 (fr)
KR (1) KR101160182B1 (fr)
CN (1) CN1909907B (fr)
AP (1) AP2507A (fr)
AT (1) ATE444068T1 (fr)
AU (1) AU2005205935B2 (fr)
BR (1) BRPI0507065B8 (fr)
CA (1) CA2553269C (fr)
CY (1) CY1109677T1 (fr)
DE (1) DE602005016890D1 (fr)
DK (1) DK1711181T3 (fr)
EA (1) EA011277B1 (fr)
ES (1) ES2333730T3 (fr)
HK (1) HK1099223A1 (fr)
HR (1) HRP20090673T1 (fr)
IL (1) IL177012A (fr)
ME (1) ME01065B (fr)
NO (1) NO337814B1 (fr)
NZ (1) NZ547615A (fr)
PL (1) PL1711181T3 (fr)
PT (1) PT1711181E (fr)
RS (1) RS51074B (fr)
SG (1) SG166019A1 (fr)
SI (1) SI1711181T1 (fr)
UA (1) UA86952C2 (fr)
WO (1) WO2005070430A1 (fr)
ZA (1) ZA200606066B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51074B (sr) * 2004-01-23 2010-10-31 Janssen Pharmaceutica N.V. Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
CA2711912A1 (fr) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Derives de quinoleine, de naphtalene, de quinoleine ou de naphtalene contraint au niveau conformation en tant qu'agents antimycobacteriens
EP2414353A1 (fr) 2009-04-01 2012-02-08 Basf Se Composés d'isoxazoline pour lutter contre les ravageurs invertébrés
WO2011138666A1 (fr) * 2010-05-06 2011-11-10 Council Of Scientific And Industrial Research Composés de thiolactone à substitution quinolylpipérazino, et procédé d'élaboration correspondant
TW201210597A (en) * 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
SG11201408238WA (en) 2012-06-13 2015-01-29 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
PL2909192T3 (pl) 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
WO2015057629A1 (fr) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Modulateurs quinolinyl à liaison alkyle de roryt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
WO2015057626A1 (fr) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Modulateurs quinolinyl de roryt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
MX370438B (es) 2014-03-24 2019-12-13 Guangdong Zhongsheng Pharmaceutical Co Ltd Derivados quinolina como inhibidores smo.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
KR101716239B1 (ko) 2015-02-12 2017-03-28 사단법인대한결핵협회 마이코박테리아의 성장 증진용 조성물 및 방법
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2019213506A1 (fr) 2018-05-04 2019-11-07 Incyte Corporation Sels d'un inhibiteur de fgfr
CN108558858A (zh) * 2018-05-23 2018-09-21 成都师范学院 硝基呋喃类抗结核化合物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CA3162010A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Derives d'un inhibiteur de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA2270123A1 (fr) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Composes, compositions et techniques afferentes, aux fins du traitement d'infections resistant aux antibiotiques
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU2437900A (en) 1999-01-20 2000-08-07 Smithkline Beecham Plc Piperidinylquinolines as protein tyrosine kinase inhibitors
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
TW200409637A (en) * 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
PT2301544E (pt) 2002-07-25 2012-12-10 Janssen Pharmaceutica Nv Novos inibidores de micobactérias
EP1687277B1 (fr) * 2003-11-20 2018-04-04 Janssen Pharmaceutica NV 2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp)
CN1882549B (zh) * 2003-11-20 2011-02-23 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮
UA89618C2 (ru) * 2003-12-05 2010-02-25 Янссен Фармацевтика Н.В. 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы
AU2004299183B2 (en) * 2003-12-10 2010-09-23 Janssen Pharmaceutica N.V. Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
RS51074B (sr) * 2004-01-23 2010-10-31 Janssen Pharmaceutica N.V. Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
EA011277B1 (ru) 2009-02-27
EA200601364A1 (ru) 2006-12-29
AU2005205935B2 (en) 2011-06-02
CA2553269A1 (fr) 2005-08-04
BRPI0507065A (pt) 2007-06-12
CN1909907B (zh) 2010-06-23
US7902225B2 (en) 2011-03-08
ES2333730T3 (es) 2010-02-26
BRPI0507065B8 (pt) 2021-05-25
DE602005016890D1 (de) 2009-11-12
CA2553269C (fr) 2012-07-10
IL177012A0 (en) 2008-04-13
PL1711181T3 (pl) 2010-02-26
KR20070001929A (ko) 2007-01-04
US20110124870A1 (en) 2011-05-26
DK1711181T3 (da) 2010-02-01
US20070093478A1 (en) 2007-04-26
CN1909907A (zh) 2007-02-07
ME01065B (me) 2012-10-20
HRP20090673T1 (hr) 2010-01-31
JP4879755B2 (ja) 2012-02-22
IL177012A (en) 2012-03-29
CY1109677T1 (el) 2014-08-13
WO2005070430A1 (fr) 2005-08-04
ATE444068T1 (de) 2009-10-15
PT1711181E (pt) 2009-12-29
AP2006003694A0 (en) 2006-08-31
EP1711181B1 (fr) 2009-09-30
AP2507A (en) 2012-11-16
UA86952C2 (uk) 2009-06-10
SI1711181T1 (sl) 2010-01-29
BRPI0507065B1 (pt) 2019-11-12
RS51074B (sr) 2010-10-31
NZ547615A (en) 2009-08-28
JP2007518776A (ja) 2007-07-12
AU2005205935A1 (en) 2005-08-04
NO20063748L (no) 2006-08-22
NO337814B1 (no) 2016-06-27
ZA200606066B (en) 2007-11-28
EP1711181A1 (fr) 2006-10-18
HK1099223A1 (en) 2007-08-10
KR101160182B1 (ko) 2012-06-26

Similar Documents

Publication Publication Date Title
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20076635L (no) Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DK1539700T3 (da) 8-hydroxyquinolin-derivater
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
UA103478C2 (ru) Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
WO2010151710A3 (fr) Composés hétérocycliques substitués utilisés en tant qu'inhibiteurs de la kinase et leur procédé d'utilisation
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
NO20080033L (no) Kinolinderivater som NK3-antagonister
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
TW200612942A (en) Thiazolinone unsubstituted quinolines
MX2007000576A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
TW200628153A (en) Novel compounds
MXPA05009282A (es) Derivados de anilina sustituidos.
MX2011012859A (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
EP1845780A4 (fr) Utilisations de derives de methylphenidate